sorafenib has been researched along with Endocarditis, Loeffler in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moretti, L; Salemi, S; Scapozza, L; Schmid, I; Simon, D; Simon, HU; Yousefi, S | 1 |
| Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P | 1 |
| Cools, J | 1 |
| Antoniu, SA | 1 |
| Cross, NC; Erben, P; Hochhaus, A; Hofmann, WK; Klippstein, T; Martin, H; Metzgeroth, G; Mousset, S; Reiter, A; Teichmann, M; Walz, C | 1 |
| Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P | 1 |
1 review(s) available for sorafenib and Endocarditis, Loeffler
| Article | Year |
|---|---|
Novel therapies for hypereosinophilic syndromes.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bone Marrow Transplantation; CD52 Antigen; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Interleukin-5; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib | 2010 |
5 other study(ies) available for sorafenib and Endocarditis, Loeffler
| Article | Year |
|---|---|
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2009 |
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Male; Mice; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib | 2009 |
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
Topics: Benzenesulfonates; Humans; Hypereosinophilic Syndrome; mRNA Cleavage and Polyadenylation Factors; Niacinamide; Nuclear Pore Complex Proteins; Oncogene Proteins; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2010 |
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2012 |
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; K562 Cells; Kidney Neoplasms; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2006 |